Logo

Genentech's Ocrevus Shorter 2-Hour Infusion Receives the US FDA's Approval for Relapsing & Primary Progressive Multiple Sclerosis

Share this

Genentech's Ocrevus Shorter 2-Hour Infusion Receives the US FDA's Approval for Relapsing & Primary Progressive Multiple Sclerosis

Shots:

  • The approval is based on ENSEMBLE PLUS study- which demonstrated similar frequency and severity of IRRs for 2hrs. Ocrevus infusion time vs conventional 3.5hrs in patients with RRMS. The initial dose is given as two 300mg infusions given 2wks. apart and a subsequent dose of single 600mg infusions were administered over a shorter- 2hrs. time
  • Results: frequency of IRRs post 600mg infusion (24.6% vs 23.1%)- majority of IRRs were mild or moderate- and >98% resolved in both groups without complication
  • Ocrevus is a humanized mAb designed to target CD20-positive B cells and is the first and only therapy approved for both RMS and PPMS

­ Ref: Genentech | Image: Xconomy

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions